Gingival enlargement is one of the adverse drug reactions associated with the administration of several drugs. Progression of gingival enlargement affects the normal oral hygiene practice and may interfere with mastication, speech, etc. It gradually becomes a source of pain and disfigurement. There is a wide variation in the presentation of clinical and histological features of such gingival enlargements. Nifedipine is one such drug of the family of calcium channel blockers that has the potential to cause gingival overgrowth in patients taking the same, although in a limited number of cases. The management of such cases requires a multi-pronged approach including thorough scaling and root planning, drug substitution, and surgical approach. This case report highlights the management of one such case of a patient taking nifedipine for the management of hypertension.
INTRODUCTION
Gingival enlargement is one of the most important yet rarely encountered entities among oral pathologies. It has a varied number of etiologies and has been consistently and frequently associated with inflammatory changes in the gingiva. Other factors associated to this condition are hereditary (familial), malignancies, adverse drug reactions, pregnancy, systemic diseases, and conditions. Drugs that most common cause gingival enlargement include anticonvulsants, calcium channel blockers, and immunosuppressants. Many of the calcium channel blockers used as antihypertensive drugs have been found to cause gingival enlargement. Nifedipine, a dihydropyridine, is a calcium channel blocker that has been widely used for the treatment of cardiovascular disease, especially hypertension. [1] It inhibits the influx of extracellular calcium ions across the membranes of cardiac and vascular smooth muscle cells without altering calcium concentrations in the blood. Although rare, the side effects of nifedipine include hypotension, headaches, flushness, dizziness, tremor, joint stiffness, peripheral edema, dermatitis, pruritis, urticaria, and gingival overgrowth. [2] [3] [4] The incidence and prevalence of nifedipine-induced gingival overgrowth is contentious. According to the literature, the prevalence ranges from 14.7% to 83%. It seems more likely to occur in males, as reported by Barak et al., who found a male to female ratio of 5:1. [1, 2, 5] The mechanism behind Drug-induced gingival overgrowth (DIGO) is not well understood. It has been suggested that there is the production of an inactive form of collagenase by fibroblasts, and it creates an imbalance in the production and degradation of collagen thereby leading to increase in the volume of gingival tissues. An altered response to bacterial plaque and hypersensitivity of subpopulations of fibroblasts to the drug have been proposed as other mechanisms to DIGO. [6] The clinical picture of gingival overgrowth shows enlargement of interdental gingiva and most frequently on the labial area of both jaws as well as buccal, palatal and distal areas of maxillary molars and premolars. Plaque accumulation and gingival bleeding are also noted commonly. [2] In general, the overgrowth is asymptomatic and affects both attached and free gingival tissues. The gingiva may appear red, shiny or spongy, at times associated with spontaneous bleeding and ulcerations. The risk factors associated with such gingival overgrowth include poor oral hygiene, pre-existing inflammation, and combination of drug therapy. [2] Patients reportedly have a series of problems with gingival overgrowth, such as speech alterations, masticatory problems, tooth migration, plaque retention, oral malodor, and compromised oral aesthetics. This overgrowth can also cause emotional and social problems such depression, anxiety, and frustration. [2] Several authors report that plaque accumulation is an essential for the development of gingival overgrowth. However, so far, no clear interconnection has been established. Some researchers have reported that subjects with poor plaque control may have more severe gingival overgrowth. Other studies have found that conventional periodontal treatment associated along with comprehensive oral hygiene program can evoke a positive treatment response, eliminating the need for surgical treatment, whereas other studies contradict such findings. [1, 2, 6] The severity of the gingival overgrowth guides the treatment plan. Initial therapy indicates usage of nonsurgical periodontal therapy, but some case reports have only found positive results with scaling, root surface instrumentation and extensive plaque control, as demonstrated by Zanatta et al., [7] Hancock and Swan, [8] and Ciantar. [9] In a number of cases, the gold standard still seems to be surgical tissue removal, but gingivectomy must be repeated periodically due to the recurrent nature of DIGO. [10] It would be helpful to the patient if a close association is established between a patient's physician and a periodontist in order to identify alternative drug regimens that can help reduce the impact of unwanted effects. [11] 
CASE REPORT
A 55-year-old male patient came to the Department of Periodontology and Oral Implantology with a complaint of swelling of gingiva and bleeding gums in relation of lower front teeth [ Figure 1a ]. Important medical history findings included a controlled hypertensive state since 3 years prior to consultation. His drug regimen was as follows: 40 mg/day of nifedipine; 320 mg/day of propranolol; with the patient taking nifedipine for 18 months. A family history of hypertension was also noted.
Intra-oral examination revealed generalized edematous gingival tissues, with the interdental papillae predominantly affected [ Figure 1a ]. A single, irregular growth is present on lower left gingiva of 32, 33, and 34. On palpation, the growth is non-tender, sessile base, firm and nodular inconsistency gingival enlargement started to appear 6 months prior to the consultation, but the patient was not able to remember the exact date. The plaque was present on nearly all surfaces, and a high gingival bleeding index was observed. Probing pocket depths of +6 mm were found around most of the teeth.
A provisional diagnosis of gingival overgrowth associated with nifedipine was made, and no other risk factors were identified. The differential diagnosis of pyogenic granuloma, peripheral giant cell granuloma, central giant cell granuloma and fibroma were also considered. Treatment consisted of conservative therapy with meticulous oral hygiene instruction, scaling, root surface instrumentation and prophylaxis. The patient was advised chlorhexidine mouth rinse 0.2% w/v twice a day. The patient's doctor was consulted, and nifedipine was replaced with enalapril 5 mg for managing hypertension. An orthopantomograph was taken to assess bone level [ Figure 1b ]. Before the first intervention, the physician recommended antibiotic prophylaxis (amoxicillin 2 g, 1 h before). 4 weeks after initial treatment, there was a notable change in the amount of inflammation and also some mild regression in the size of the overgrowth [ Figure 1c and d].
As the patient was insistent to get his overgrowth removed without any delay, a second stage surgical intervention was planned. An internal bevel incision was given around the affected teeth and was continued as a sulcular incision to the opposite side [ Figure 1e ]. The flap was reflected, and then the granulation tissue was debrided properly [ Figure 1f ]. The overgrowth area was re-contoured properly, and tissue samples were taken for biopsy. Suturing was done, and the patient was relieved with appropriate post-operative care instructions [ Figure 1g ]. The patient was advised Digesic-P (diclofenac sodium 50 mg and paracetamol 500 mg) twice a day for 7 days and Droxyl (cefadroxil 500 mg) twice a day for 7 days.
Histological examination was done with an H and E stained section showing epithelium and connective tissue. Epithelium was stratified squamous in nature. Underlying connective tissue was highly cellular with a large number of chronic inflammatory cells, blood vessels filled with red blood cells, and budding capillaries were also seen [ Figure 1i ]. At 8 weeks after the initial treatment associated with the suspension of nifedipine and intensive oral hygiene and surgical intervention, there was a marked reduction in generalized gingival overgrowth [ Figure 1h ]. Follow-up was rendered impossible for subsequent month due to the patient's personal problems, but afterward the established treatment plan continued. Four months following the first intervention with the oral hygiene program, clinical parameters showed a great improvement, with a significant reduction in gingival overgrowth, demonstrating the potential effectiveness of non-surgical periodontal therapy in severe cases of gingival overgrowth [ Figure 1j ].
DISCUSSION
Drug-induced gingival over growth is a significant problem for periodontists and this undesirable effect is more closely associated with particular drugs, such as phenytoin, cyclosporine A and nifedipine. [11, 12] The literature considers different treatment options for DIGO: Non-surgical and surgical approaches. [10] Most articles suggest the surgical approach as a gold standard for treatment while others have advocated a non-surgical approach and some have proposed a combined approach to manage cases of drug-induced gingival enlargement. [1, 2, 6, 7, 13, 14] However, some studies have failed to confirm the success of non-surgical approaches, such as those by Seymour and Smith. [15] Furthermore, it has been reported that adequate plaque control may aid in preventing or retarding the recurrence of gingival enlargement in surgically treated cases. [6, 12] The findings of this case report confirm that a surgical approach followed after non-surgical therapy may be considered as the comprehensive treatment of nifedipineinduced gingival enlargement, even in advanced cases. Multiple case reports have demonstrated similar positive results when DIGO was treated with supra-gingival and sub-gingival scaling and an intensive oral hygiene program along with surgical intervention. [12, 13, 16] CONCLUSION It is very important for the periodontist to work in conjunction with the patient's doctor in an attempt to change medication or determine the possibility of discontinuing a drug. As demonstrated by this report, in some cases, the doctor can suspend the drug or exchange it for another that does not produce this adverse effect and can help decrease the degree of the gingival enlargement. Non-surgical treatment followed by proper surgical approaches can produce a positive treatment response. It is therefore suggested that a proper medical history of the patient and proper consultation with the physician of the patient for substituting the 
